Gene Therapy Restores Hearing in Congenital Deafness Trial Milestone

Congenital deafness has long been one of the most intractable problems in medicine, but a new era is unfolding for a specific and surprisingly common form of inherited hearing loss. A systematic review published in the Journal of Translational Medicine by Li-Ping Peng, Yi Ren, Shi-Hua Yin and colleagues at Guangxi Medical University charts the extraordinary trajectory of OTOF gene therapy over the past three years, from preclinical vector design to multicenter human trials and, in 2026, the first regulatory approval of a gene therapy for congenital deafness. The review, which synthesizes the molecular pathology, vector engineering and clinical evidence accumulated to date, arrives at a striking conclusion: adeno-associated virus (AAV)-mediated replacement of the OTOF gene is both safe and feasible, and it has already produced clinically significant hearing improvements in most treated children.

The condition at the heart of this story is autosomal recessive deafness type 9, known as DFNB9, which is caused by mutations in the OTOF gene and accounts for roughly 2 to 8 percent of hereditary cases of congenital sensorineural hearing loss. What makes DFNB9 uniquely suited to gene replacement is the anatomy of its defect. Unlike many forms of genetic deafness in which the delicate hair cells of the inner ear are missing or degenerated, DFNB9 patients retain structurally intact hair cells. The problem lies instead in the synaptic machinery: otoferlin, the protein encoded by OTOF, is essential for the calcium-triggered release of neurotransmitter at the ribbon synapse, the specialized junction through which hair cells transmit sound-encoded signals to the auditory nerve. In the absence of functional otoferlin, the ear’s microphone still works, but the signal never reaches the brain.

This synaptic bottleneck defines both the pathology and the therapeutic opportunity. Because the hair cells are alive and waiting for their missing protein, restoring even a partial supply of otoferlin could, in principle, reopen the auditory pathway without requiring cell replacement or regeneration. That biological premise has now been tested at scale. Between 2024 and 2026, the research team led by Yilai Shu at Fudan University published a remarkable sequence of clinical studies in The Lancet, Nature Medicine and Nature, progressing from unilateral treatment in the first human trial, to bilateral administration, and finally to a 42-participant multicenter cohort with follow-up extending as long as 2.5 years. Across these studies, the evidence consistently pointed in the same direction: children who had been profoundly deaf from birth began to hear, and in many cases to develop speech and language, after a single surgical delivery of the therapeutic vector.

Getting there required solving formidable technical problems, and the review devotes substantial attention to the vector engineering that made the trials possible. The OTOF gene is enormous by viral-vector standards, far exceeding the roughly 4.7-kilobase packaging capacity of a single AAV particle. The solution was dual-vector technology, in which the otoferlin coding sequence is split across two AAV genomes and reconstituted inside the target cell through mechanisms such as trans-splicing, hybridization of overlapping fragments, or intein-mediated protein trans-splicing. Each strategy carries trade-offs in reconstitution efficiency and fidelity, and much of the preclinical work of the past three years has focused on optimizing which split design delivers the most functional otoferlin to hair cells with the least immunological and toxicological burden.

Equally critical has been the refinement of the delivery system itself. AAV vectors must reach the hair cells of the cochlea, a structure encased in bone and fluid-filled compartments that are notoriously difficult to access without causing additional damage. The review highlights three converging advances: the design of AAV capsids with improved tropism for inner hair cells, the development of hair cell-specific promoters that restrict otoferlin expression to the correct cell type and reduce off-target expression, and minimally invasive inner ear delivery methods, typically via the round window membrane, that allow the vector to perfuse the cochlear duct while preserving residual hearing and cochlear architecture. Together, these innovations moved OTOF gene therapy from animal models into the operating room within a remarkably short window.

The clinical results have been the most consequential development. In the successive Fudan-led trials, treated children showed substantial recovery of auditory function, with many progressing from profound deafness to thresholds compatible with speech perception and, in several cases, spontaneous language development. The safety record has been encouraging: across the cohorts, AAV-mediated OTOF replacement was well tolerated, with no treatment-related serious adverse events reported that undermined the feasibility of the approach. The consistency of benefit across unilateral, bilateral and multicenter designs strengthened the case that the effect was real and reproducible rather than an artifact of a single center or a small sample. The culmination came in 2026, when the United States Food and Drug Administration approved Otarmeni (lunsotogene parvec-cwha), the first OTOF gene therapy, a milestone the review describes as pivotal for the entire field of inner ear medicine.

Yet the review is equally clear about the challenges that remain. The first is the therapeutic window. Gene replacement must occur before auditory pathways and speech circuits have irreversibly reorganized in the absence of input, and the precise age range during which treatment confers maximal benefit has not been fully delineated. Most treated children have been young, reflecting the assumption that earlier is better, but the boundaries of that window, and whether older children or adults with DFNB9 could also benefit, remain open questions. Defining the window precisely will require longer follow-up and careful correlation of treatment age with outcomes, a task that the ongoing trials are only beginning to address.

The second cluster of challenges is industrial and economic. Producing AAV vectors at clinical scale under current Good Manufacturing Practice conditions is a recognized bottleneck for the entire gene therapy field, and the dual-vector requirement of OTOF therapy doubles the dose burden, since each treatment requires two full AAV genomes per target cell. Manufacturing complexity translates directly into cost, and the review notes that the prohibitive price of gene therapy creates accessibility barriers that could leave most of the world’s DFNB9 patients untreated. Because DFNB9 is distributed globally and congenital deafness screening is uneven, the gap between what the science can achieve and what health systems can deliver is likely to be one of the defining tensions of the coming decade.

Long-term safety is the third unresolved issue. With a maximum follow-up of 2.5 years, the clinical evidence base cannot yet speak to durability of hearing restoration or to late-emerging adverse effects such as immune responses to the vector or the reconstituted protein. The review emphasizes that the absence of long-term safety data is a critical gap that only time and continued surveillance can fill. It also points toward the broader horizon of precision intervention: OTOF is a proof of principle, but the same vector engineering, delivery and trial infrastructure now being validated could be adapted to other genetic forms of deafness, each with its own molecular target and technical constraints.

Taken together, the review by Peng, Ren, Yin and their colleagues documents one of the fastest bench-to-bedside journeys in modern medicine. In roughly three years, OTOF gene therapy moved from preclinical vector design through the first unilateral human trial, bilateral treatment and a 42-participant multicenter study, to FDA approval of the first therapy for congenital deafness. The molecular logic was elegant from the start: a structurally intact but synaptically silent inner ear, waiting for a single missing protein. What the trials demonstrated is that, with the right capsid, the right promoter and the right surgical delivery, that protein can be supplied and hearing can begin. The remaining work, defining the therapeutic window, scaling manufacturing, extending safety surveillance and lowering cost, is formidable but tractable, and it will determine whether this new era of precision intervention for congenital deafness reaches the children worldwide who stand to benefit from it.

Subject of Research: AAV-mediated OTOF gene replacement therapy for DFNB9 congenital deafness

Article Title: OTOF gene therapy: from the first human trial to a new era of precision intervention for congenital deafness

Article References: Peng, L.-P., Ren, Y., Liu, Y., Shen, L., Zhu, B.-B., Ban, Y.-Q., Liang, C.-L., Chen, L., He, J.-N., Wei, R.-D., & Yin, S.-H. (2026). OTOF gene therapy: from the first human trial to a new era of precision intervention for congenital deafness. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08890-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08890-9

Keywords: OTOF, DFNB9, gene therapy, adeno-associated virus, congenital deafness, sensorineural hearing loss, ribbon synapse, clinical trial, FDA approval, AAV vectors, inner ear delivery, clinical translation